{"id":"https://openalex.org/W2270191540","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps282","title":"A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).","display_name":"A phase Ib study of oral panobinostat (LBH589) administered with 5-azacitidine (5-Aza) in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML).","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2270191540","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps282","mag":"2270191540"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.tps282","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps282","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps282","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064625563","display_name":"Oliver Gerhard Ottmann","orcid":"https://orcid.org/0000-0001-9559-1330","observed_orcids":["https://orcid.org/0000-0001-9559-1330"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"O. G. Ottmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014838075","display_name":"Pierre Fenaux","orcid":"https://orcid.org/0000-0002-0468-3553","observed_orcids":["https://orcid.org/0000-0002-0468-3553"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"P. Fenaux","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047951694","display_name":"Michael L\u00fcbbert","orcid":"https://orcid.org/0000-0003-1186-1650","observed_orcids":["https://orcid.org/0000-0003-1186-1650"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. L\u00fcbbert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082924494","display_name":"Daniel J. DeAngelo","orcid":"https://orcid.org/0000-0001-7865-2306","observed_orcids":["https://orcid.org/0000-0001-7865-2306"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. J. DeAngelo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061026876","display_name":"Guillermo Garcia\u2010Manero","orcid":"https://orcid.org/0000-0002-3631-2482","observed_orcids":["https://orcid.org/0000-0002-3631-2482"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Garcia-Manero","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079069209","display_name":"Kapil N. Bhalla","orcid":"https://orcid.org/0000-0001-5209-5126","observed_orcids":["https://orcid.org/0000-0001-5209-5126"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. N. Bhalla","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055740968","display_name":"Mikkael Aaron Sekeres","orcid":"https://orcid.org/0000-0003-2009-6524","observed_orcids":["https://orcid.org/0000-0003-2009-6524"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. A. Sekeres","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037093409","display_name":"Frank L\u00fcdicke","orcid":"https://orcid.org/0000-0001-6786-8347","observed_orcids":["https://orcid.org/0000-0001-6786-8347"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"F. L\u00fcdicke","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"H. J. Weber","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. J. Weber","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021403417","display_name":"Ivo J. Winiger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I. J. Winiger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"TPS282","last_page":"TPS282"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10269","display_name":"Epigenetics and DNA Methylation","score":0.006200000178068876,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/panobinostat","display_name":"panobinostat","score":0.9950000047683716},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.996999979019165},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9679999947547913},{"id":"https://openalex.org/keywords/chronic-myelomonocytic-leukemia","display_name":"chronic myelomonocytic leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":1.0},{"id":"https://openalex.org/keywords/deacetylase-inhibitors","display_name":"deacetylase inhibitors","score":0.824999988079071},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.9459999799728394},{"id":"https://openalex.org/keywords/epigenetic-therapy","display_name":"epigenetic therapy","score":0.9100000262260437},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7590000033378601},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8330000042915344},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9670000076293945},{"id":"https://openalex.org/keywords/dna-methylation","display_name":"DNA methylation","score":0.6169999837875366},{"id":"https://openalex.org/keywords/gene-expression","display_name":"gene expression","score":0.7979999780654907}],"concepts":[{"id":"https://openalex.org/C2776239401","wikidata":"https://www.wikidata.org/wiki/Q416451","display_name":"Azacitidine","level":5,"score":0.8576958179473877},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8362948894500732},{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.7857434749603271},{"id":"https://openalex.org/C2779277951","wikidata":"https://www.wikidata.org/wiki/Q5255196","display_name":"Demethylating agent","level":5,"score":0.6296614408493042},{"id":"https://openalex.org/C2777928532","wikidata":"https://www.wikidata.org/wiki/Q1088072","display_name":"Chronic myelomonocytic leukemia","level":4,"score":0.5935890078544617},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5636371374130249},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.5626829862594604},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.545131266117096},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.5102479457855225},{"id":"https://openalex.org/C2776012956","wikidata":"https://www.wikidata.org/wiki/Q17125294","display_name":"Hypomethylating agent","level":5,"score":0.4714905917644501},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.44894126057624817},{"id":"https://openalex.org/C2780235182","wikidata":"https://www.wikidata.org/wiki/Q1181878","display_name":"Decitabine","level":5,"score":0.41769129037857056},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.37167030572891235},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.2129269242286682},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.16246667504310608},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.08801817893981934},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.tps282","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps282","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps282","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2592755553","https://openalex.org/W2565453288","https://openalex.org/W2573909369","https://openalex.org/W2755246038","https://openalex.org/W2591000412","https://openalex.org/W2564549938","https://openalex.org/W2563465935","https://openalex.org/W1989336886","https://openalex.org/W2567356540","https://openalex.org/W2618292946"],"abstract_inverted_index":{"TPS282":[0],"Background:":[1],"The":[2,280],"demethylating":[3,37,64],"agent":[4,38],"5-Aza":[5,187,232],"is":[6,44,83,198,270,283],"an":[7,24],"integral":[8],"therapy":[9,185,193],"in":[10,14,92,121,154,229],"MDS":[11],"and":[12,29,39,53,66,76,97,127,137,151,159,177,188,208,218,247,294,304],"AML,":[13],"which":[15],"epigenetic":[16,51,192],"modifications":[17],"contributing":[18],"to":[19,48,71,112,132,253,308],"disease":[20,273],"are":[21,32,182,194,242,251],"well-documented.":[22],"Despite":[23],"overall":[25],"survival":[26],"benefit,":[27],"better":[28],"earlier":[30],"responses":[31],"needed.":[33],"Combination":[34],"of":[35,119,148,210,285,296],"a":[36,40,45,84,109,128,211,221],"deacetylase":[41],"inhibitor":[42],"(DACi)":[43],"rational":[46],"strategy":[47],"reverse":[49],"aberrant":[50],"alterations":[52],"the":[54,114,266],"malignant":[55],"phenotype.":[56],"Preclinical":[57],"data":[58],"indicate":[59],"that":[60,87],"sequential":[61],"treatment":[62],"with":[63,95,123,165,174,186,226,231],"agents":[65],"DACi":[67],"targets":[68],"multiple":[69],"mechanisms":[70],"synergistically":[72],"de-repress":[73],"silenced":[74],"genes":[75],"exert":[77],"antileukemic":[78,90,138],"activity.":[79],"Panobinostat":[80],"(PAN;":[81],"LBH589)":[82],"potent":[85],"pan-DACi":[86],"has":[88],"demonstrated":[89],"activity":[91,139],"patients":[93],"(pts)":[94],"AML":[96,173],"MDS.":[98],"This":[99],"phase":[100,111,131],"Ib,":[101],"open-label,":[102],"multicenter,":[103],"dose-finding":[104],"study":[105],"comprises":[106],"2":[107],"phases:":[108],"dose-escalation":[110],"determine":[113],"maximum":[115],"tolerated":[116],"dose":[117,125,245],"(MTD)":[118],"PAN":[120,197],"combination":[122,230],"standard":[124],"5-Aza,":[126],"subsequent":[129],"expansion":[130],"further":[133],"evaluate":[134],"safety,":[135],"tolerability,":[136],"(FPFV":[140],"Dec":[141],"2,":[142],"2009).":[143],"Other":[144,328],"objectives":[145],"include":[146,290,301],"assessment":[147],"gene":[149],"expression":[150],"methylation":[152],"status":[153],"peripheral":[155],"blood":[156],"cells":[157],"before":[158],"during":[160],"therapy.":[161],"Methods:":[162],"Adult":[163],"pts":[164,241,250,259],"IPSS":[166],"INT-2":[167],"or":[168,172,277,314,318],"high-risk":[169],"MDS,":[170],"CMML,":[171],"multi-lineage":[175],"dysplasia":[176],"\u226430%":[178],"marrow":[179],"blasts":[180],"who":[181],"candidates":[183],"for":[184,265],"have":[189],"not":[190],"received":[191],"eligible.":[195],"Oral":[196],"administered":[199],"on":[200],"Days":[201],"(D)":[202],"3,":[203],"5,":[204],"8,":[205],"10,":[206],"12,":[207],"15":[209],"28-D":[212],"cycle,":[213],"starting":[214],"at":[215,263],"20":[216],"mg":[217],"guided":[219],"by":[220],"Bayesian":[222],"logistic":[223],"regression":[224],"model":[225],"overdose":[227],"control,":[228],"(75":[233],"mg/m2":[234],"sc":[235],"D":[236],"1\u20137).":[237],"At":[238],"least":[239],"3":[240],"required":[243,252],"per":[244],"cohort":[246],"\u22659":[248],"evaluable":[249],"declare":[254],"MTD.":[255],"An":[256],"additional":[257],"11":[258],"will":[260],"be":[261],"enrolled":[262],"MTD":[264],"dose-expansion":[267],"phase.":[268],"Treatment":[269],"continued":[271],"until":[272],"progression,":[274],"unacceptable":[275],"toxicity,":[276],"consent":[278],"withdrawal.":[279],"primary":[281],"endpoint":[282],"incidence":[284],"dose-limiting":[286],"toxicity.":[287],"Secondary":[288],"endpoints":[289,300],"type,":[291],"duration,":[292],"frequency,":[293],"relatedness":[295],"adverse":[297],"events.":[298],"Exploratory":[299],"clinical":[302],"response":[303],"hematologic":[305],"improvement":[306],"according":[307],"IWG":[309],"criteria.":[310],"Author":[311],"Disclosure":[312],"Employment":[313],"Leadership":[315],"Position":[316],"Consultant":[317],"Advisory":[319],"Role":[320],"Stock":[321],"Ownership":[322],"Honoraria":[323],"Research":[324],"Funding":[325],"Expert":[326],"Testimony":[327],"Remuneration":[329],"Novartis":[330,334,335,349,350],"Bristol-Myers":[331,336,346],"Squibb,":[332,337,347],"Celgene,":[333,338,348],"Cepahlon,":[339],"Johnson":[340],"&":[341],"Johnson,":[342],"Merck,":[343],"Novartis,":[344],"Roche":[345]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}